Clinical Trial Update: A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for transgenic lymphocyte immunization targeting telomerase in stage III melanoma patients (Stage IIIB/IIIC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Transgenic Lymphocyte Immunization (TLI) Against Telomerase

Snippet

Sponsor: Cosmo Bioscience | Conditions: Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma | Phase 2 | Status: UNKNOWN